March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Richard Pratley, MD is a paid Novo Nordisk, Inc. spokesperson.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

Novo Nordisk already has broad FDA approvals ... 2 diabetes who also have atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD). It would become the first add-on ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.

Novo Nordisk said the Food and Drug Administration ... disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday. The approval makes Ozempic ...

Novo Nordisk on Saturday said its diabetes ... average in patients with diabetes and established heart disease, with or without chronic kidney disease. The Danish drugmaker presented the results ...